# RxAll

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rxall

- Industry: Healthcare IT
- Headquarters: New Haven, US
- Website: www.rxall.com
- Total disclosed funding: $2M
- Latest round: Seed (Sep 1, 2021)
- Investors on record: 5

## About

Based in the US, RxAll, Inc. is a health-tech company that provides digital solutions for ensuring the authenticity and quality of medicines, combating counterfeit drugs in critical healthcare markets.RxAll, Inc. was founded in 2016 in New Haven, US, as a pioneer in providing technological solutions for authenticating pharmaceuticals. The company has engaged in 7 deals, with its latest funding round taking place in September 2021, raising USD 2.050 mn. The company is led by Adebayo Alonge, who has a background in healthcare technology.RxAll is a health-tech platform that focuses on providing digital infrastructure primarily for pharmacies, hospitals, and wholesalers to ensure the availability of authentic medicines. The company's flagship products include the RxScanner, which employs artificial intelligence to conduct real-time chemical analysis of drug samples, returning quality assessments to users in just 20 seconds. Additionally, RxAll offers the RxDelivered marketplace, which connects buyers and sellers of authenticated drugs, as well as RxPay, a financial solution that supports pharmacies and wholesalers in preventing stock-outs. These offerings aim to tackle the critical issue of counterfeit medicines, enhancing the trustworthiness of drug supply chains while ensuring that patients receive high-quality, non-counterfeit medications. RxAll operates across various geographical markets, including multiple countries in Africa, where the need for reliable healthcare solutions is especially pressing.RxAll generates revenue through a diversified transactional structure that includes both B2B and direct-to-consumer models. The company’s financial services, particularly through RxPay, create partnerships with pharmacies and wholesalers, facilitating funding to maintain inventory without increasing drug prices. The RxDelivered marketplace operates on a commission basis, allowing for seamless transactions between verified sellers and buyers of authentic medicines. Customers benefit from a streamlined purchasing process, and pharmacies gain access to already authenticated drugs at competitive prices. RxAll's focus on critical healthcare technology not only fosters customer loyalty but also positions the firm as a leader in combating counterfeit drugs in emerging markets.In September 2021, RxAll, Inc. raised USD 2.050 mn in seed funding from new investor LoftyInc Capital Management. The funds will be utilized to support the development of upcoming products, including enhancements to the RxScanner and an expansion of the RxDelivered marketplace. RxAll plans to enter additional markets in Africa and the Middle East by 2023, targeting regions with significant demand for genuine pharmaceutical solutions.

## Funding rounds

- Seed, Sep 1, 2021 — LoftyInc Capital Management
- Seed, May 13, 2021 — SOSV, HAX
- Seed, Feb 17, 2020, $2M — SOSV, Plug and Play, Angel Challenge
- Seed, Oct 16, 2019 — SOSV, HAX

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- HAX — Seed
- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Seed
- Angel Challenge — Seed
- LoftyInc Capital Management (https://capitalatlas.ai/funds/loftyinc-capital-management) — Seed